Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$22.71 -10.03%

-$3.24 today

Market cap
$3.85B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 1.81M

Average 3.67M

Returns on capital

Tango Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-29.3%

avg -72.6%

ROIC

-29.3%

avg -33.6%

ROA

-25.5%

avg -25.5%

Analysis

ROA is currently the strongest return metric at -25.5% versus its period average of -25.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Barbara L. Weber

Executive OfficerUSD 1.24M69——

Daniella Beckman

Executive OfficerUSD 1.24M47184.30K0.15%

Adam S. Crystal

President of Research & DevelopmentUSD 928.21K49——

Matthew Gall

Chief Financial OfficerUSD 717.62K4940.00K0.03%

Malte Peters

President, Chief Executive Officer & DirectorUSD 148.32K64367.50K0.30%

Elizabeth Pingpank Hickin

Vice President of IR & Corporate Communications————

Julie Carretero

Chief Human Resources Officer—54——

Julie Fogarty

Senior VP, General Counsel & Corporate Secretary————

Antoni Ribas

Founder & Member of Scientific Advisory Board—59——

William G. Kaelin Jr.

Founder & Member of Scientific Advisory Board—68——

Alan Ashworth

Founder & Member of Scientific Advisory Board—65——

Jannik N. Andersen

Chief Scientific Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

30

$8.08M

Net Transaction Value

−$8.08M

Net selling

Most Active

Crystal Adam

21 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 11, 26

Crystal Adam

Direct

Sell$125K
Nov 2, 26

Crystal Adam

Direct

Sell$86.8K
Nov 2, 26

Crystal Adam

Direct

Sell$25.3K
Nov 2, 26

Newcomb Jessica

Direct

Sell$124.1K
Nov 2, 26

Newcomb Jessica

Direct

Sell$33.6K
Oct 1, 26

Crystal Adam

Direct

Sell$645.6K
Oct 1, 26

Crystal Adam

Direct

Sell$15.2K
Sep 22, 26

Newcomb Jessica

Direct

Sell$16K
Sep 22, 26

Newcomb Jessica

Direct

Sell$122.2K
Sep 22, 26

Newcomb Jessica

Direct

Sell$60.4K

1–10 of 30

Summary

Insiders reported 0 buys worth $0.00 and 30 sells worth $8.08M over the last 12 months. That adds up to net selling of $8.08M. Crystal Adam was the most active insider with 21 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+35.9%
+68.1% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +35.9% over three years. Forward estimates point to Revenue at +68.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Tango Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TNGX's management, answered from reported figures.

Who manages TNGX?

Tango Therapeutics, Inc. (TNGX) lists 12 active executives. The top listed executive is Matthew Gall, Chief Financial Officer.

Are TNGX insiders buying or selling?

Recent insider activity shows net selling of $23.91M.